Proteome Sciences and Moffitt Cancer Center collaborate on clinical mass spec assays for assessment of cancer patien
LONDON—Proteome Sciences PLC, a global leader in applied proteomics and peptidomics, has entered into a collaboration agreement with the renowned Moffitt Cancer Center to develop mass spectrometry assays measuring certain key signaling and repair pathway proteins that can be adapted for tumor biopsy analysis in the clinic.
According to Proteome Sciences, the technical collaboration will enable the extension of Moffitt's activities to incorporate a large number of key proteins and post-translational modifications to rapidly translate laboratory tests into the direct management of cancer patients.
"We believe that knowledge of the molecular switches operating within each individual tumor will allow better selection and monitoring of treatment efficacy," said Dr. John Koomen, principal investigator at the cancer center, in a statement.
These new methods, capable of simultaneously measuring these changes across several pathways, are urgently needed to deliver better outcomes in all cancers, stated Dr. Ian Pike, chief operating officer of Proteome Sciences.
"We identified the expertise of the Koomen lab as being highly complementary to our own focus of profiling post-translational modifications in major human disease," he added. "We are delighted to be working with John and look forward to launching a number of new MS assays arising from this collaboration."
Located in Tampa, Fla., the Moffitt Cancer Center is a National Institutes of Health Comprehensive Cancer Center. The center has 14 affiliates in Florida, one in
Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer.